iRadimed Corporation
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving iRadimed Corporation now
Current reporting with the operating signal separated from the noise.
IRadimed Corporation revenue up 0.5% to 20.5M in Q2 2026
Investors are testing whether iRadimed Corporation’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Iradimed Corporation Declares Regular Quarterly Cash Dividend for the Second Quarter Ended June 30, 2026, Payable on August 28, 2026
The story matters when it changes iRadimed Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Iradimed Corporation Provides Earnings Guidance for the Third Quarter and Reaffirms Earnings Guidance for the Full Year of 2026
Investors are testing whether iRadimed Corporation’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.IRADIMED Corporation 8-K Filing July 31, 2026: Financial Results, Key SEC Details, and NASDAQ Listing
The development tests whether iRadimed Corporation can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.(IRMD) IRADIMED CORPORATION Expects Q3 Revenue Range $23.0M - $24.5M
Investors are testing whether iRadimed Corporation’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Earnings Flash (IRMD) IRADIMED CORPORATION Reports Q2 Revenue $20.5M, vs. FactSet Est of $20.4M
Investors are testing whether iRadimed Corporation’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.GUIDANCE: (IRMD) IRADIMED CORPORATION Expects Q3 Revenue Range $23.0M - $24.5M
Investors are testing whether iRadimed Corporation’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest IRMD filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
iRadimed Corporation, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →